Changes in resource use and outcomes for patients with Migraine treated with sumatriptan : A managed care perspective.
Migraine headaches result in significant patient suffering and high costs to managed care organizations and employers.
Studies that evaluate patient outcomes and the financial consequences of migraine treatment are important from a clinical and an economic perspective.
This prospective, observational study assessed the outcomes of migraineurs in a mixed model staff/independent practice association managed care organization for patients previously diagnosed as having migraine who received their first prescription for sumatriptan.
Data collected included medical as well as pharmacy claims and patient surveys to measure changes in satisfaction, health-related quality of life, workplace productivity, and nonworkplace activity after sumatriptan therapy was initiated.
A total of 178 patients completed the study.
Results showed significant decreases in the mean number of migraine-related physician office visits, emergency department visits, and medical procedures in the 6 months after sumatriptan therapy compared with the 6 months before sumatriptan was used (P<. 05).
Four of the health-related quality-of-life dimensions and the physical component summary score measured by the SF-36 (which is a valid, reliable general health status instrument) showed significant improvements at 6 months compared with patients'scores before use of sumatriptan (P<. 05). (...)
Mots-clés Pascal : Migraine, Protocole thérapeutique, Pharmacocinétique, Sumatriptan, Efficacité traitement, Qualité vie, Productivité travail, Evaluation, Prospective, Satisfaction, Homme, Etats Unis, Amérique du Nord, Amérique, Douleur, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Cérébrovasculaire pathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Antimigraineux, Agoniste, Récepteur sérotoninergique 5-HT1, Stimulant sérotoninergique, Economie santé
Mots-clés Pascal anglais : Migraine, Therapeutic protocol, Pharmacokinetics, Sumatriptan, Treatment efficiency, Quality of life, Labour productivity, Evaluation, Prospective, Satisfaction, Human, United States, North America, America, Pain, Nervous system diseases, Central nervous system disease, Cerebral disorder, Cerebrovascular disease, Cardiovascular disease, Vascular disease, Antimigrainous agent, Agonist, 5-HT1 Serotonine receptor, Serotonin agonist, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0269921
Code Inist : 002B02B09C. Création : 16/11/1999.